Lupus & antiphospholipid syndrome
Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active
Authors' conclusion
In patients with SLE with clinical disease activity, the proportion attaining LLDAS and DORIS under usual care conditions is suboptimal. Longer maintenance of these states is significantly associated with reduced risk of flare.
Study context
- Population
- Patients with systemic lupus erythematosus (SLE) with clinically active disease, not in Lupus Low Disease Activity State (LLDAS) or Definition of Remission in SLE (DORIS), in a multinational cohort93.2% female
- Participants
- 1,991 patients
- Outcome
- Frequency and determinants of LLDAS and DORIS attainment
Methodological detailsmultinational
- Multinational
Main finding
As reported in the abstract
median follow-up 2.5 (IQR 0.7-4.5) years
Achieved LLDAS
70.9%
Achieved DORIS
55.6%
Observational data: associations, not effects.
Further findings
Flare after first LLDAS and DORIS attainment
- Flare(s) after first LLDAS
- 47.0%
- Flare(s) after first DORIS
- 47.5%
- Longer cumulative time at target and antimalarial use associated with longer time to flare
- Dose reduction in GC and immunosuppressants associated with shorter time to flare
Organ damage accrual after first LLDAS and DORIS attainment · within 24 months
- Damage accrual after first LLDAS
- 9.5%
- Damage accrual after first DORIS
- 7.9 %
- Longer cumulative time at target and antimalarial use associated with longer time to damage accrual
- Reduction in immunosuppressants correlated with shorter time to damage accrual
Original publication
Prevalence, Determinants, and Outcomes of Low Disease Activity and Remission Attainment in Patients With Systemic Lupus Erythematosus That Is Clinically Active. Arthritis Care Res (Hoboken). Published 29 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →